ESTRO 37 Abstract book

S915

ESTRO 37

Results Fifty-nine metastatic patients treated for 60 lesions, 10p were treated in OM group and 49p were treated in OP group. The median age was 63 years old. The most common primary cancers were gastrointestinal neoplasm (n=20) and lung tumors (n=11). Median follow-up post- SBRT treatment was 13 months (range, 1-160months); 1- and 2-year PFS and LC was 62,5% and 60%, and 100% and 96,2%, respectively. The median OS was 62,75 months versus 35,96 months in the OM group and OP group (p=0,10). Radiation therapy was well tolerated, toxicity was grade 2 pain and fatigue in 2 cases. No Grade ≥3 toxicity was documented. Conclusion Oligometastatic patients treated with radical radiotherapy may achieve long-term progression-free survival, without significant treatment-related toxicity. While waiting for data from randomized trials, the use of radical radiation therapy in oligometastatic patients should be considered a valuable option, and its recommendation should be individualized. EP-1703 Exercise medicine is the new radiotherapy adjunct - when co-located and timetabled with treatment. N.A. Spry 1 , F. Singh 2 , D. Galvao 2 , D. Taaffe 2 , R. Chee 3 , M. Davis 4 , P. O'Brien 5 , R. Newton 2 1 Genesis Cancer Care Shenton House, Radiation Oncology, Joondalup, Australia 2 Edith Cowan University, Exercise Medicine Research Institute, Joondalup WA, Australia 3 GenesisCancerCare Shenton House, Radiation Oncology, Joondalup WA, Australia 4 Genesis Cancer Care, Radiation Oncology, Wembley WA, Australia 5 Genesis Cancer Care, Radiation Oncology, Newcastle NSW, Australia Purpose or Objective Exercise offers great potential as an adjunct therapy to reverse treatment-related side-effects and increase quality and quantity of life in people with cancer. In practice, uptake is poor due to community and medical belief that patients should rest during curative radiation cancer treatment especially if already undergoing chemotherapy and the overwhelming logistics of self- arranging training at other locations during daily radiation. Edith Cowan University (ECU) exercise medicine has a long experience successfully completing exercise studies in cancer patients, and were given an opportunity to co-locate a fully equipped training facility within the treatment section of a new Genesis radiation service, Shenton House. We report initial observational experience to demonstrate feasibility and benefits of this patient-centric approach and highlight areas for improvement. Material and Methods During the first 3-years, two training windows, on separate days, were available for patients undertaking long course curative-intent radiation treatment. Patients underwent aerobic and resistance exercise (60mins) either before or after their treatment sessions. At any given time up to a maximum of 12 patients were supervised by an exercise physiologist employing an ECUexercise medicine program for 6 weeks(12 sessions). A optional detailed offsite assessment was offered, where upper and lower body muscle strength (1-RM), physical function (6m usual and fast walk, 6m backwards walk, 400m walk, chair rise and stair climb) were assessed at

baseline, end of resistance training and at 3 months follow-up. Compliance was defined as >8 attendances. Quality of life data was also collected Results 235 patients (mean age 60.1years) consented to participate at the site and of these patients 69 opted for the off-site testing assessments. Baseline demographics; age, sex, cancer site were not different between tested and not tested. Compliance>75%, non-attendance was attributed to chemo/radiation side effects, fatigue, family issues, other. Attendance for subsequent offsite testing was 44/69 at end of treatment and 27/69 at 3 months. No adverse events for exercise were identified. All functional assessments showed improvements at all time points. End of radiation improvements ( p <0.05) were observed for muscle strength (7.1-21.5%) and physical function (3.3-10.1%), with no significant adverse change in body composition. At 3 months, the improvement was maintained ( p <0.05) in leg press (21.4%) and seated row (9.1%) muscle strength, and for the 6m usual (9.2%), 6m backwards (18.5%), 400m walk (5%) and chair rise (9.8%) test. Conclusion We attribute the high participation and attendance levels to co-location and concurrent training time. Significant functional improvements followed, contrasting with expected declines from rest therapy. We suggest this approach is workable and effective and introduces patients to Exercise medicine and longer-term health benefits beyond those described here. EP-1704 How efficacious is Ziverel® for symptomatic relief of acute radiation-induced esophagitis? E. Carrasco-Esteban 1 , F. López-Campos 1 , S. Sastre- Gallego 1 , P. Barrionuevo Castillo 1 , M. Martín-Martín 1 , R. Hernanz-de Lucas 1 , C. Vallejo-Ocaña 1 , S. Sancho-García 1 1 Ramon y Cajal University Hospital, Radiation Oncology, Madrid, Spain Purpose or Objective To evaluate the efficacy of ZIVEREL ® for symptomatic relief in a retrospective cohort of patients with acute radiation-induced esophagitis receiving oncologic treatment with radiotherapy alone or radiochemotherapy. ZIVEREL ® is a new oral medical device composed of hyaluronic acid, chondroitin sulfate, and poloxamer 407. Radiation-induced esophagitis is a dose-limiting toxicity in oncologic treatment with radiotherapy or radiochemotherapy, and sometimes a limiting factor for treatment . Material and Methods Between February 2016-July 2017, we evaluated 41 patients (33 men and 8 women) treated with ZIVEREL ® , with a diagnosis of lung cancer (63.41%), gastric cancer (31.71%), and esophageal cancer (4.88%) who developed acute radiation-induced esophagitis (CTCAE grade 1 [60.98%] and grade 2 [39.02%]) during treatment with radiotherapy alone (36.59%) or radiochemotherapy (63.41%). The median age was 69 years (range, 38 to 90 years).